Press Releases

• July 11, 2023

IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042

• May 31, 2023

IconOVir Bio to Present at Jefferies Healthcare Conference

• March 7, 2023

IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference

• November 10, 2022

IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022

• October 10, 2022

IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer

• October 5, 2022

IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022

• September 14, 2022

IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium

• June 23, 2022

IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors

• June 6, 2022

IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer

• June 3, 2022

IconOVir Bio to Present at Jefferies Healthcare Conference